Aura Biosciences
AURA
6.41
-0.06
-0.85%
Aura Biosciences
US · AURA
#3544 by market cap
Listed 2021
6.41
-0.06
-0.85%
Live - 5344 symbols - heartbeat 105s ago
· 2026-10-08 10:09
Pre-market
6.32
-2.19%
After-hours
6.46
0.00%
- Market cap
- 664.23M
- P/E (TTM)i
- -3.70
- P/Bi
- 2.11
- EPSi
- -1.76
- Div yieldi
- 0.00%
- 52W posi
- 35%
Reader sentiment
Are you bullish or bearish on AURA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.52M | 4.16M | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M |
| Research & development | 19.62M | 18.04M | 25.16M | 42.24M | 65.23M | 73.30M | 90.30M |
| Operating profit | -24.14M | -22.21M | -35.25M | -60.30M | -84.99M | -96.12M | -112.79M |
| Pretax profit | -24.20M | -22.21M | -35.25M | -58.76M | -76.27M | -86.81M | -106.08M |
| Tax | -- | -- | -- | 0 | 137.00K | 112.00K | 108.00K |
| Net profit | -24.20M | -22.21M | -35.25M | -58.76M | -76.41M | -86.92M | -106.19M |
| Basic EPS | -2 | -2 | -9 | -2 | -2 | -2 | -2 |
| Diluted EPS | -1.74 | -1.54 | -8.95 | -1.96 | -1.93 | -1.75 | -1.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.69M | 5.73M | 5.73M | 5.34M | 6.91M | 17.32M |
| Research & development | 23.34M | 22.88M | 22.18M | 21.90M | 27.96M | 30.75M |
| Operating profit | -29.04M | -28.61M | -27.91M | -27.24M | -34.87M | -48.07M |
| Pretax profit | -27.47M | -26.97M | -26.10M | -25.54M | -33.67M | -45.61M |
| Tax | 18.00K | 48.00K | 26.00K | 15.00K | 11.00K | 29.00K |
| Net profit | -27.48M | -27.02M | -26.13M | -25.56M | -33.69M | -45.64M |
| Basic EPS | -1 | 0 | 0 | 0 | -1 | 0 |
| Diluted EPS | -0.55 | -0.47 | -0.40 | -0.37 | -0.50 | -0.48 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 33.35M | 18.46M | 153.70M | 196.70M | 231.79M | 160.62M | 149.74M |
| Cash & ST investments | 32.45M | 17.39M | 149.06M | 188.81M | 226.15M | 151.09M | 144.24M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 37.06M | 22.10M | 160.03M | 223.94M | 255.08M | 182.50M | 169.43M |
| Total current liabilities | 6.15M | 2.66M | 7.36M | 10.46M | 12.36M | 14.91M | 18.38M |
| Short-term debt | -- | -- | 615.00K | 2.96M | 2.69M | 3.15M | 3.24M |
| Long-term debt | 49.00K | -- | -- | -- | -- | -- | -- |
| Total liabilities | 124,461,000.00 | 2,741,000.00 | 7,715,000.00 | 28,352,000.00 | 29,227,000.00 | 30,533,000.00 | 32,517,000.00 |
| Total equity | -87.41M | 19.36M | 152.32M | 195.58M | 225.85M | 151.97M | 136.91M |
| Retained earnings | -94.68M | -116.89M | -152.14M | -210.90M | -287.31M | -374.23M | -480.42M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 134.52M | 183.96M | 170.12M | 149.74M | 118.50M | 329.03M |
| Cash & ST investments | 127.99M | 177.31M | 161.87M | 144.24M | 114.73M | 323.84M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 155.40M | 204.40M | 190.02M | 169.43M | 137.68M | 348.13M |
| Total current liabilities | 12.16M | 14.85M | 18.82M | 18.38M | 16.71M | 19.56M |
| Short-term debt | 3.17M | 3.20M | 3.22M | 3.24M | 3.27M | 3.29M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 27,435,000.00 | 29,768,000.00 | 33,357,000.00 | 32,517,000.00 | 30,430,000.00 | 32,862,000.00 |
| Total equity | 127.97M | 174.63M | 156.67M | 136.91M | 107.25M | 315.27M |
| Retained earnings | -401.71M | -428.73M | -454.86M | -480.42M | -514.10M | -559.74M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -20.67M | -24.32M | -32.41M | -54.60M | -63.85M | -79.81M | -84.74M |
| Depreciation & amortization | 509.00K | 831.00K | 831.00K | 1.18M | 1.30M | 1.22M | 1.13M |
| Free cash flow | -22.89M | -25.09M | -34.54M | -55.70M | -64.56M | -81.06M | -85.19M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 78.70M | 8.55M | 95.79M | 0 | 52.57M |
| Ending cash balance | 32.54M | 17.49M | 149.21M | 122.37M | 41.85M | 32.46M | 60.28M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -23.36M | -20.77M | -20.14M | -20.47M | -29.89M | -32.50M |
| Depreciation & amortization | 291.00K | 286.00K | 280.00K | 272.00K | 274.00K | 260.00K |
| Free cash flow | -23.54M | -20.81M | -20.19M | -20.65M | -30.00M | -32.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 3.29M | 2.77M | -- | -- |
| Ending cash balance | 38.99M | 108.14M | 48.32M | 60.28M | 85.56M | 68.60M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -211.88 | -33.78 | -36.26 | -46.01 | -73.52 |
| ROA %i | -65.31 | -75.07 | -50.72 | -30.61 | -31.90 | -39.73 | -60.35 |
| ROIC %i | -- | -- | -205.52 | -32.80 | -36.81 | -46.31 | -69.42 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -80.29 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.42 | 6.94 | 20.90 | 18.81 | 18.76 | 10.77 | 8.15 |
| Quick ratioi | 5.28 | 6.54 | 20.27 | 18.06 | 18.30 | 10.13 | 7.85 |
| Debt / assetsi | 0.13 | 0.00 | 0.61 | 9.31 | 7.67 | 10.28 | 10.26 |
| LT debt / equityi | -- | -- | 0.24 | 9.15 | 7.47 | 10.28 | 10.32 |
| Interest coveragei | -4,839.00 | -7,401.00 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -56.24 | -55.39 | -64.26 | -73.52 | -95.57 | -53.49 |
| ROA %i | -48.51 | -47.97 | -53.86 | -60.35 | -76.70 | -47.42 |
| ROIC %i | -54.09 | -53.25 | -60.89 | -69.42 | -85.82 | -51.52 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 11.06 | 12.39 | 9.04 | 8.15 | 7.09 | 16.82 |
| Quick ratioi | 10.52 | 11.94 | 8.60 | 7.85 | 6.87 | 16.65 |
| Debt / assetsi | 11.87 | 8.86 | 9.34 | 10.26 | 12.34 | 4.77 |
| LT debt / equityi | 11.93 | 8.54 | 9.28 | 10.32 | 12.80 | 4.22 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 10:09:53 · For reference only, not investment advice and not tailored to your situation.